[NICE Consultation] Type 2 diabetes in adults: management – SGLT2 inhibitors for chronic kidney disease (update)

NICE |  September 2021 | Type 2 diabetes in adults: management – SGLT2 inhibitors for chronic kidney disease (update) In development [GID-NG10246]Expected publication date: 24 November 2021

This guidance will partially update the following:

This consultation is open until 29 September 2021 at 5pm

Full details, and consultation documents are available from NICE

NICE Medtech innovation briefing [MIB227 t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes

NICE | 22 September 2020 | Medtech innovation briefing [MIB227 t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes

NICE has developed a medtech innovation briefing (MIB) on t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes.

Full details from NICE

[NICE update] Type 2 diabetes in adults: management

NICE |  August 2019 | Type 2 diabetes in adults: management

NICE has updated Type 2 diabetes in adults: management, this guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

Full details from NICE

NICE: Dapagliflozin with insulin for treating type 1 diabetes

NICE | August 2019| Dapagliflozin with insulin for treating type 1 diabetes

Today (28 August 2019) has published  final guidance on an innovative treatment for type 1 diabetes. Dapagliflozin is the first licenced oral add-on therapy to insulin in type 1 diabetes

Dapagliflozin (brand name Forxiga) with insulin is available on the NHS. It is a possible treatment for type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2, when insulin alone does not control blood sugar levels well enough, if:

  • you are on insulin doses of more than 5 units per kilogram of body weight per day and
  • you have done a structured education programme that includes information about diabetic ketoacidosis, and
  • treatment is started and supervised by a consultant physician specialising in endocrinology and diabetes.

Further details are available from NICE